Targets › LPA
4 programs from 4 companies in 11 trials: 9 Phase 3, 1 Phase 2, 1 Phase 1; Cardiovascular; next expected readout Jul 2027.
Apo(a) is the main constituent of lipoprotein(a) (Lp(a)). It has serine proteinase activity and is able of autoproteolysis. (UniProt, P08519)
Open in Phaseline: the race on LPA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Pelacarsen (TQJ230) LPA mRNA antisense inhibitor | LPA | Phase 3 | Atherosclerotic Cardiovascular Disease (ASCVD); Hyperlipoproteinemia (a); Cardiovascular Disease and Lipoprotein(a); Atherosclerotic Cardiovascular Disease … | Feb 2028 |
| Amgen | Olpasiran LPA mRNA rnai inhibitor | LPA | Phase 3 | Atherosclerotic Cardiovascular Disease; Cardiovascular Disease | Mar 2028 |
| Eli Lilly | Lepodisiran Sodium Lipoprotein(a) synthesis inhibitor (antisense oligonucleotide) | LPA | Phase 3 | Atherosclerotic Cardiovascular Disease (ASCVD); Atherosclerosis | Mar 2029 |
| Bisirna Therapeutics (Suzhou) | BSA204 LPA antisense oligonucleotide inhibitor | LPA | Phase 1 | Dyslipidemias | Jul 2027 |
Atherosclerotic Cardiovascular Disease (2) Cardiovascular Disease (2) Atherosclerotic Cardiovascular Disease (ASCVD) (2) Hyperlipoproteinemia (a) (1) Cardiovascular Disease and Lipoprotein(a) (1) Aortic Stenosis (1) Dyslipidemias (1) Atherosclerosis (1)
other (3), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.